Page 33 - Anjali Singh

Meril Life Sciences eyes 5-fold revenue growth over the next 5 years

Currently, 55 per cent of Meril's revenue comes from its international business, through its presence in over 150 countries and subsidiaries in more than 25 nations such as Germany, Russia and Brazil

Tier-II cities see surge in medical consultations, outpacing metros: Report

Metro cities also experienced a surge in medical consultations, with Mumbai leading at 92.07 per cent, followed by Hyderabad at 91.63 per cent and Chennai at 83.4 per cent

Utkarsh Small Finance Bank proposes reverse merger with holding entity

The bank has said it has taken note of the proposal and the Board of Directors of the lender will meet in due course and evaluate the proposal and other options to achieve regulatory compliance

Medical groups raise concerns around India-EFTA after leaked documents

Doctors Without Borders (MSF), Public Eye, and Delhi Network of Positive People expressed concern that the deal, which is nearing completion, includes harmful intellectual property (IP) proposals

Glenmark Pharma Q3 results: Standalone loss at Rs 20 cr, revenue dips 38.4%

Glenmark is going through a transitionary phase on account of divestment of Glenmark Life Sciences, says MD

Eris Lifesciences Q3 results: Profit flat at Rs 102 crore, revenue up 16%

On a sequential basis, the company saw a 3.40 per cent decline in revenue along with Profit After Tax (PAT), which also declined by 16.77 per cent

India witnesses decline in vector-borne tropical diseases in last 2 years

NCVBDC numbers reveal a downward trend in these diseases over the past few years, indicating successful control efforts

Dr Reddy's Laboratories R&D facility gets VAI status in USFDA inspection

Last year in December, during the Good Manufacturing Practice (GMP) and Pre-Approval Inspection at the same facility concluded with three observations

MRF Q3 results: PAT rises threefold to Rs 509 crore, revenue up 9.17%

The company opted not to disclose figures for its international operations, citing their insignificance in meeting the disclosure threshold specified in the Indian Accounting Standards

Health tech startup Neodocs raises Rs 16.6 cr in seed funding round

Company that makes smartphone-based medical test kits will use the financing to expand business

Declining raw material prices help to boost tyre makers' profitability

Among raw materials used by the tyre industry, Brent crude oil prices saw a 6 per cent drop year-on-year

JK Tyre and Industries Q3 results: Profit rises three-fold to Rs 221 cr

On a sequential basis, the company exhibited a 5.39 per cent decline in revenue along with PAT, which also declined by 8.79 per cent. The EBITDA grew by 61 per cent year-on-year, reaching Rs 563 crore

Entero Healthcare Solutions set to launch Rs 1,600-crore IPO on February 9

In FY23, Entero Healthcare reported Rs 33,00.20 crore in revenue from operations with a gross profit of Rs 268.34 crore

Alembic Pharma Q3 results: Profit up 48% as raw material cost declines

This increase in PAT was attributed to tax deduction, decline in the cost of materials consumed, and improvement in Ebitda

Thyrocare acquires Think Health Diagnostics, expands into home ECG services

With this strategic acquisition, Thyrocare will expand its footprint in the pre-policy medical check-up segment for the insurance market

Metropolis Healthcare Q3 results: PAT down 24% due to Chennai floods

On a sequential basis, the company exhibited a 5.63 per cent decline in revenue along with PAT, which declined by 23.41 per cent

Torrent Pharma Q3 results: Profit after tax up 51% at Rs 443 crore

Torrent Pharmaceuticals' share price rose by 0.51 per cent, ending the day's trade at Rs 2,524 apiece on the Bombay Stock Exchange (BSE)

Glenmark, Pfizer launch Abrocitinib in India for Atopic Dermatitis

The prevalence of atopic dermatitis in India has risen over the past three decades, with approximately 5.9 per cent of adults affected, of which 4.4 per cent suffer from a severe form of the disease

Dr Reddy's Lab Q3 results: Net profit rises 11% on strong US, EU sales

For the Indian business in Q3 FY24, the revenue stood at Rs 1,180 crore Y-o-Y with a growth of 5 per cent and a sequential decline of 1 per cent

Piramal Pharma Q3FY24 results: Company posts profit at Rs 19.3 crore

On a sequential basis, the company exhibited a 2.47 percent increase in revenue whereas the PAT declined by 51.07 percent